Adverse events reported in oncology clinical trials don’t always match what patients experience. What is behind this disconnect and is it possible to reconcile?

My patient Betsy Lewis has found the balance in which we neither welcome death nor push it away – and still celebrates her ...

Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track Preclinical ...

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

Exelixis’ (EXEL) lead drug, Cabometyx, a tyrosine kinase inhibitor (TKI), maintains a dominant position for the treatment of ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...